{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T18:52:07Z","timestamp":1768675927366,"version":"3.49.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100013229","name":"C17 Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013229","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.ejca.2021.04.006","type":"journal-article","created":{"date-parts":[[2021,5,9]],"date-time":"2021-05-09T10:54:12Z","timestamp":1620557652000},"page":"126-135","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Health care utilisation and costs associated with different treatment protocols for newly diagnosed childhood acute lymphoblastic leukaemia: A population-based study in Ontario, Canada"],"prefix":"10.1016","volume":"151","author":[{"given":"Sumit","family":"Gupta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rinku","family":"Sutradhar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uma","family":"Athale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mylene","family":"Bassal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vicky","family":"Breakey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul J.","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serina","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariana","family":"Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veda","family":"Zabih","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petros","family":"Pechlivanoglou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason D.","family":"Pole","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Mittmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2021.04.006_bib1","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1056\/NEJMra1400972","article-title":"Acute lymphoblastic leukemia in children","volume":"373","author":"Hunger","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2021.04.006_bib2","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1200\/JCO.19.02892","article-title":"Impact of intrathecal triple therapy versus intrathecal methotrexate on disease-free survival for high-risk B-lymphoblastic leukemia: Children's Oncology Group Study AALL1131","volume":"23","author":"Salzer","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.04.006_bib3","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/S1470-2045(15)00363-0","article-title":"Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial","volume":"16","author":"Place","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2021.04.006_bib4","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1200\/JCO.19.01692","article-title":"Improved CNS control of childhood acute lymphoblastic leukemia without cranial irradiation: St Jude Total Therapy Study 16","volume":"35","author":"Jeha","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.04.006_bib5","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1002\/pbc.23197","article-title":"Cost-effectiveness of treatment of childhood acute lymphoblastic leukemia with chemotherapy only: the influence of new medication and diagnostic technology","volume":"557","author":"van Litsenburg","year":"2011","journal-title":"Pediatr Blood Canc"},{"issue":"6","key":"10.1016\/j.ejca.2021.04.006_bib6","first-page":"779","article-title":"Economic evaluation of treatment for acute lymphoblastic leukaemia in childhood","volume":"23","author":"Rae","year":"2014","journal-title":"Eur J Canc Care"},{"issue":"1","key":"10.1016\/j.ejca.2021.04.006_bib7","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/cam4.1206","article-title":"Cost comparison by treatment arm and center-level variations in cost and inpatient days on the phase III high-risk B acute lymphoblastic leukemia trial AALL0232","volume":"7","author":"DiNofia","year":"2018","journal-title":"Canc Med"},{"key":"10.1016\/j.ejca.2021.04.006_bib8","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/j.1651-2227.2000.tb00087.x","article-title":"Cost analysis of the treatment of acute childhood lymphocytic leukaemia according to Nordic protocols","volume":"89","author":"Rahiala","year":"2000","journal-title":"Acta Paediatr"},{"issue":"2","key":"10.1016\/j.ejca.2021.04.006_bib9","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/cam4.583","article-title":"A retrospective analysis of treatment-related hospitalization costs of pediatric, adolescent, and young adult acute lymphoblastic leukemia","volume":"5","author":"Kaul","year":"2016","journal-title":"Canc Med"},{"key":"10.1016\/j.ejca.2021.04.006_bib10","doi-asserted-by":"crossref","first-page":"e132","DOI":"10.1200\/EDBK_278171","article-title":"Cutting to the front of the line: immunotherapy for childhood acute lymphoblastic leukemia","volume":"40","author":"McNeer","year":"2020","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"27","key":"10.1016\/j.ejca.2021.04.006_bib11","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1200\/JCO.2014.59.1636","article-title":"Childhood acute lymphoblastic leukemia: progress through collaboration","volume":"33","author":"Pui","year":"2015","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2021.04.006_bib12","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1182\/blood-2010-12-322909","article-title":"Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group","volume":"118","author":"Matloub","year":"2011","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.ejca.2021.04.006_bib13","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1200\/JCO.2011.37.8018","article-title":"Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group","volume":"30","author":"Hunger","year":"2012","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.ejca.2021.04.006_bib14","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1200\/JCO.2012.43.2070","volume":"31","author":"Vrooman","year":"2013","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2021.04.006_bib15","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/ijc.11004","article-title":"Childhood cancer registries in Ontario, Canada: lessons learned from a comparison of two registries","volume":"105","author":"Greenberg","year":"2003","journal-title":"Int J Canc"},{"issue":"6","key":"10.1016\/j.ejca.2021.04.006_bib16","doi-asserted-by":"crossref","first-page":"281","DOI":"10.3747\/co.21.2143","article-title":"Health system costs for stage-specific breast cancer: a population-based approach","volume":"21","author":"Mittmann","year":"2014","journal-title":"Curr Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2021.04.006_bib17","doi-asserted-by":"crossref","first-page":"615.e1","DOI":"10.1016\/j.ajog.2015.11.021","article-title":"Phase-specific healthcare costs of cervical cancer: estimates from a population-based study","volume":"214","author":"Liu","year":"2016","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ejca.2021.04.006_bib18","series-title":"Guidelines on person-level costing using administrative databases in Ontario","author":"Wodchis","year":"2013"},{"issue":"17","key":"10.1016\/j.ejca.2021.04.006_bib19","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1200\/JCO.19.03024","article-title":"Impact of asparaginase discontinuation on outcome in childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group","volume":"38","author":"Gupta","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.04.006_bib20","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1182\/blood.V97.5.1211","article-title":"Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01","volume":"97","author":"Silverman","year":"2001","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.ejca.2021.04.006_bib21","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1182\/blood.2020007702","article-title":"Optimizing therapy in the modern age: differences in length of maintenance therapy in acute lymphoblastic leukemia","volume":"137","author":"Teachey","year":"2021","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.ejca.2021.04.006_bib22","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1200\/JCO.2017.74.4946","article-title":"Reduced-intensity delayed intensification in standard risk pediatric acute lymphoblastic leukemia defined by undetectable minimal residual disease: results of an international randomized trial (AIEOP-BFM ALL 2000)","volume":"36","author":"Schrappe","year":"2018","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.ejca.2021.04.006_bib23","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1002\/pon.2009","article-title":"A prospective study to determine the costs incurred by families of children newly diagnosed with cancer in Ontario","volume":"21","author":"Tsimicalis","year":"2012","journal-title":"Psycho Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2021.04.006_bib24","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.27458","article-title":"A cost-effectiveness analysis of Erwinia asparaginase therapy in children with acute lymphoblastic leukemia","volume":"66","author":"Kloos","year":"2019","journal-title":"Pediatr Blood Canc"},{"issue":"5","key":"10.1016\/j.ejca.2021.04.006_bib25","doi-asserted-by":"crossref","first-page":"753","DOI":"10.3324\/haematol.2012.073510","article-title":"Cost-analysis of treatment of childhood acute lymphoblastic leukemia with asparaginase preparations: the impact of expensive chemotherapy","volume":"98","author":"Tong","year":"2013","journal-title":"Haematologica"},{"issue":"no. 15_suppl","key":"10.1016\/j.ejca.2021.04.006_bib26","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS7568","article-title":"A phase II\/III study of JZP-458 in patients with acute lymphoblastic leukemia (ALL)\/lymphoblastic lymphoma (LBL) who are hypersensitive to E. coli-delivered asparaginases","volume":"38","author":"Maese","year":"2020","journal-title":"J Clin Oncol"},{"issue":"34","key":"10.1016\/j.ejca.2021.04.006_bib27","doi-asserted-by":"crossref","first-page":"3874","DOI":"10.1200\/JCO.2014.55.5763","article-title":"Pharmacokinetic and pharmacodynamic properties of calaspargase pegol Escherichia coli L-asparaginase in the treatment of patients with acute lymphoblastic leukemia: results from Children's Oncology Group Study AALL07P4","volume":"32","author":"Angiolillo","year":"2014","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2021.04.006_bib28","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.1111\/1475-6773.12823","article-title":"Impact of the 340B drug pricing program on cancer care site and spending in Medicare","volume":"53","author":"Jung","year":"2018","journal-title":"Health Serv Res"},{"issue":"2","key":"10.1016\/j.ejca.2021.04.006_bib29","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1177\/1043454216646533","article-title":"Administration of home intravenous chemotherapy to children by their parents","volume":"34","author":"McCall","year":"2017","journal-title":"J Pediatr Oncol Nurs"},{"key":"10.1016\/j.ejca.2021.04.006_bib30","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/leu.2014.229","article-title":"Long-term outcome of a pediatric inspired regimen used for adults aged 18-50 years with newly diagnosed acute lymphoblastic leukemia","volume":"29","author":"DeAngelo","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.ejca.2021.04.006_bib31","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1182\/blood-2018-10-881961","article-title":"A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403","volume":"14","author":"Stock","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2021.04.006_bib32","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1136\/heartjnl-2014-305637","article-title":"A cardiovascular disease policy model that predicts life expectancy taking into account socioeconomic deprivation","volume":"101","author":"Lewsey","year":"2015","journal-title":"Heart"},{"key":"10.1016\/j.ejca.2021.04.006_bib33","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"issue":"Suppl_1","key":"10.1016\/j.ejca.2021.04.006_bib34","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V130.Suppl_1.SCI-39.SCI-39","volume":"134","author":"Brown","year":"2019","journal-title":"Blood"},{"issue":"S2","key":"10.1016\/j.ejca.2021.04.006_bib35","first-page":"S28","article-title":"Impact of childhood cancer drug wastage on pediatric oncology programs in Ontario, Canada","volume":"66","author":"Bradley","year":"2019","journal-title":"Pediatr Blood Canc"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804921002276?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804921002276?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:31:44Z","timestamp":1760733104000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804921002276"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":35,"alternative-id":["S0959804921002276"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2021.04.006","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Health care utilisation and costs associated with different treatment protocols for newly diagnosed childhood acute lymphoblastic leukaemia: A population-based study in Ontario, Canada","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2021.04.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}